Current therapy for Lambert–Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment

References

• Orphanet: Lambert–Eaton myasthenic syndrome. Available at: http://www.orpha.net [Last accessed 22 January 2010]
   Google Scholar
• Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956;187:612-3
   Web of Science ®Google Scholar
• Verschuuren JJGM, Wirtz PW, Titulaer MJ, et al. Available treatment options for the management of Lambert–Eaton myasthenic syndrome. Expert Opin Pharmacother 2006;7:1323-36
   PubMedGoogle Scholar
• Wirtz PW, Smallegange TM, Wintzen AR, et al. Differences in clinical features between the Lambert–Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg 2002;104:359-63
   PubMed Web of Science ®Google Scholar
• O’Neill JH, Murray NMF, Newsom-Davis J. The Lambert–Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111:577-96
   Google Scholar
• Maddison P, Newsom-Davis J, Mills KR, et al. Favourable prognosis in Lambert–Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999;353:117-8
   PubMed Web of Science ®Google Scholar
• Elias A. Pathobiology and staging of small cell carcinoma of the lung. UpToDate. Available at: http://www.uptodate.com/online/content/topic.do?topicKey=lung_ca/5407&selectedTitle=1%7E150&source=search_result [Last accessed 22 January 2010]
   Google Scholar
• Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006;13:682-90
   PubMed Web of Science ®Google Scholar
• Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006;13:691-9
   PubMed Web of Science ®Google Scholar
• Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert–Eaton myasthenic syndrome. Neurology 1996;47:678-83
   PubMed Web of Science ®Google Scholar
• Commission of the European Communities. Commission decision of 18/12/2002 relating to the designation of medicinal product ‘3,4-diaminopyridine phosphate’ as an orphan medicinal product. Brussels: C(2002)5445, 2002
   Google Scholar
• Committee for medicinal products for human use. Committee for medicinal products for human use summary of positive opinion for ZENAS, International Nonproprietary Name (INN): amifampridine. London: EMEA/CHMP/655953/2009, 2009
   Google Scholar
• Seneviratne U, de Silva R. Lambert–Eaton myasthenic syndrome. Postgrad Med J 1999;75:516-20
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert–Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002;73:766-8
   PubMed Web of Science ®Google Scholar
• Gracey DR, Southorn PA. Respiratory failure in Lambert–Eaton myasthenic syndrome. Chest 1987;91:716-8
   PubMed Web of Science ®Google Scholar
• Orphanet: Myasthenia gravis. Available at: http://www.orpha.net [Last accessed 22 January 2010]
   Google Scholar
• Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert–Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995;58:85-7
   PubMed Web of Science ®Google Scholar
• Motomura M, Lang B, Johnston I, et al. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert–Eaton myasthenic syndrome. J Neurol Sci 1997;147:35-42
   PubMed Web of Science ®Google Scholar
• Maddison P, Newsom-Davis J, Mills KR. Distribution of electrophysiological abnormality in Lambert–Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1998;65:213-7
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, Wirtz PW, Kuks JBM, et al. The Lambert–Eaton myasthenic syndrome 1988–2008: a clinical picture in 97 patients. J Neuroimmunol 2008;201–2:153-8
   Web of Science ®Google Scholar
• Wirtz PW, Willcox N, van der Slik AR, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert–Eaton myasthenic syndrome. J Neuroimmunol 2005;159:230-7
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, Wirtz PW, Willems LNA, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert–Eaton myasthenic syndrome. J Clin Oncol 2008;26:4276-81
   PubMed Web of Science ®Google Scholar
• Zivaljević M, Popović S, Vujkov T. [Lambert-Eaton myasthenic syndrome – a rare manifestation of paraneoplastic syndrome in ovarian cancer – case report]. Med Pregl 2005;58:495-7
   PubMedGoogle Scholar
• Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol 2002;20:4665-72
   PubMed Web of Science ®Google Scholar
• Pelayo Alvarez M, Gallego Rubio O, Bonfill Cosp X, et al. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2009;CD001990
   Google Scholar
• Kelly K. First-line chemotherapy for small cell lung cancer. UpToDate. Available at: http://www.uptodate.com/online/content/topic.do?topicKey=lung_ca/6976&selectedTitle=2%7E150&source=search_result [Last accessed 22 January 2010]
   Google Scholar
• Roberts A, Perera S, Lang B, et al. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 1985;317:737-9
   PubMed Web of Science ®Google Scholar
• Peterlin BL, Flood W, Kothari MJ. Use of intravenous immunoglobulin in Lambert–Eaton myasthenic syndrome. J Am Osteopath Assoc 2002;102:682-4
   PubMedGoogle Scholar
• Pellkofer HL, Voltz R, Kuempfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert–Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 2009;40:305-8
   PubMed Web of Science ®Google Scholar
• Ueda T, Kanda F, Kobessho H, et al. ‘Dropped head syndrome’ caused by Lambert–Eaton myasthenic syndrome. Muscle Nerve 2009;40:134-6
   PubMed Web of Science ®Google Scholar
• Kostera-Pruszczyk A, Ryniewicz B, Rowinska-Marcinska K, et al. Lambert–Eaton myasthenic syndrome in childhood. Eur J Paediatr Neurol 2009;13:194-6
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert–Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009;86:44-8
   PubMed Web of Science ®Google Scholar
• Thomsen RH, Wilson DF. Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J Pharmacol Exp Ther 1983;227:260-5
   PubMed Web of Science ®Google Scholar
• Murray NMF, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981;31:265-71
   PubMed Web of Science ®Google Scholar
• Lundh H, Nilsson O, Rosén I. Treatment of Lambert–Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984;34:1324-30
   PubMed Web of Science ®Google Scholar
• Molgó J, Lundh H, Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol 1980;61:25-34
   PubMed Web of Science ®Google Scholar
• Maddison P, Newsom-Davis J. Treatment for Lambert–Eaton myasthenic syndrome. Cochrane Database Syst Rev 2005;CD003279
   Google Scholar
• Lemeignan M, Millart H, Lamiable D, et al. Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Res 1984;304:166-9
   PubMed Web of Science ®Google Scholar
• Lundh H, Nilsson O, Rosén I. Novel drug of choice in Eaton–Lambert syndrome. J Neurol Neurosurg Psychiatry 1983;46:684-5
   PubMed Web of Science ®Google Scholar
• McEvoy KM, Windebank AJ, Daube JR, et al. 3,4-diaminopyridine in the treatment of Lambert–Eaton myasthenic syndrome. N Engl J Med 1989;321:1567-71
   PubMed Web of Science ®Google Scholar
• Sanders DB, Massey JM, Sanders LL, et al. A randomized trial of 3,4-diaminopyridine in Lambert–Eaton myasthenic syndrome. Neurology 2000;54:603-7
   PubMed Web of Science ®Google Scholar
• Sanders DB, Howard JF Jr, Massey JM. 3,4-diaminopyridine in Lambert–Eaton myasthenic syndrome and myasthenia gravis. Ann N Y Acad Sci 1993;681:588-90
   PubMed Web of Science ®Google Scholar
• Oh SJ, Claussen GG, Hatanaka Y, et al. 3,4-diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 2009;40:795-800
   PubMed Web of Science ®Google Scholar
• Murray NMF, Newsom-Davis J, Karni Y, et al. Oral 3,4-diaminopyridine in the treatment of the Lambert–Eaton myasthenic syndrome (LEMS). Proceedings of the meeting of the Association of British Neurologists held jointly with the Polish Neurological Society in London, April 1984. J Neurol Neurosurg Psychiatry 1984;47:1052
   Web of Science ®Google Scholar
• Flet L, Polard E, Guillard O, et al. 3,4-Diaminopyridine safety in clinical practice: an observational, retrospective cohort study. J Neurol 2010;doi:10.1007/s00415-009-5442-6
   Google Scholar
• Spatt J, Chaix R, Mamoli B. Epileptic and non-epileptic seizures in multiple sclerosis. J Neurol 2001;248:2-9
   PubMed Web of Science ®Google Scholar
• Boerma CE, Rommes JH, van Leeuwen RB, et al. Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert–Eaton myasthenic syndrome. J Toxicol Clin Toxicol 1995;33:249-51
   PubMed Web of Science ®Google Scholar
• Lundh H, Nilsson O, Rosén I, et al. Practical aspects of 3,4-diaminopyridine treatment of the Lambert–Eaton myasthenic syndrome. Acta Neurol Scand 1993;88:136-40
   PubMed Web of Science ®Google Scholar
• Kanzato N, Motomura M, Suehara M, et al. Lambert–Eaton myasthenic syndrome with ophthalmoparesis and pseudoblepharospasm. Muscle Nerve 1999;22:1727-30
   PubMed Web of Science ®Google Scholar
• Burton JM, Bell CM, Walker SE, et al. 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology 2008;71:1833-4
   PubMed Web of Science ®Google Scholar
• Schwam E. Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med 2009: published online 12 May 2009, doi:10.1016/j.jemermed.2009.04.037
   Google Scholar
• Limited FDA survey of compounded drug products. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2003. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm155725.htm [Last accessed 22 January 2010]
   Google Scholar
• Raust JA, Goulay-Dufaÿ S, Le Hoang MD, et al. Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products. J Pharm Biomed Anal 2007;43:83-8
   PubMed Web of Science ®Google Scholar
• Common technical document Zenas® 10 mg, scored tablets – 3,4-DAP phosphate (INN: amifampridine). Module 2.4. Non-clinical overview
   Google Scholar
• Common technical document Zenas® 10 mg, scored tablets – 3,4-DAP phosphate (INN: amifampridine). Module 2.5. Clinical overview
   Google Scholar
• Funck-Bretano C. Relative bioavailability study of 3,4-DAP administered as a salt or a base. DAPSEL study. Clinical study report. February 2006
   Google Scholar
• Common technical document Zenas® 10 mg, scored tablets – 3,4-DAP phosphate (INN: amifampridine). Module 5.3.5.4.3. Prospective collection of safety data from patients treated with 3,4-diaminopyridine under French ATU program
   Google Scholar
• Warning letter sent by AFSSaPS to health professionals on December 11th 2006
   Google Scholar